Business, energy, technology, markets and global industry news from Business News Today

Volixibat

PharmaDeviceNews Volixibat
Representative image: Rare liver disease research is gaining fresh attention as Mirum Pharmaceuticals reports new EASL 2026 data on volixibat, brelovitug, and LIVMARLI.
Pharma & Biotech

Why clinicians and investors are watching Mirum Pharmaceuticals after its EASL 2026 update

Find out how Mirum Pharmaceuticals’ EASL 2026 data could reshape rare liver disease treatment and investor sentiment.

Read More
Representative image of a hepatology researcher reviewing rare liver disease clinical data, reflecting Mirum Pharmaceuticals’ EASL 2026 updates on volixibat, brelovitug and maralixibat across PSC, HDV and PFIC programs.
Pharma & Biotech

Can volixibat and brelovitug expand Mirum Pharmaceuticals’ rare liver disease ambitions?

Mirum Pharmaceuticals’ EASL 2026 data deepen its rare liver disease strategy. Find out what changes for PSC, HDV and PFIC care.

Read More
Representative image: Clinical researchers review liver disease imaging and trial data as Mirum Pharmaceuticals prepares to share VISTAS study results for volixibat in primary sclerosing cholangitis.
Pharma & Biotech

Is volixibat the next major growth lever for Mirum Pharmaceuticals beyond LIVMARLI?

Mirum has commercial momentum. VISTAS will test whether volixibat can extend that rare liver disease story into PSC.

Read More